Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 107

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR 4.5 : Results from ENESTfreedom

Jose Valentín García Gutiérrez, MD PhD, Jerald P. Radich, MD, Andreas Hochhaus, MD, Giuseppe Saglio, MD PhD, Tamas Masszi, MD PhD Prof., Andrzej Hellmann, MD PhD, Jesper Stentoft, MD PhD, María Teresa Gomez Casares, MD PhD, Eibhlin Conneally, MB, PhD MRCP, MRCPath, Philipp D le Coutre, MD, Norbert Gattermann, MD, Bruno Martino, MD, Susanne Saussele, MD, Francis J. Giles, MD FRCPI, FRCPath, Paola Aimone, MD, Sai Li, MD PhD, Ksenia Titorenko, MS, David M. Ross, MD MBBS, PhD FRACP, FRCPA

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-137388

Published: 2020

Journal Articles

Analyses of Predictors of Durable Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Frontline or Second-Line Nilotinib

Jerald P. Radich, MD, Andreas Hochhaus, MD, Francis J. Giles, MD FRCPI, FRCPath, David M. Ross, MD, Giuseppe Saglio, MD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Dong-Wook Kim, Rafik Fellague-Chebra, MD, Manu Sondhi, MD PhD, Ranjan Tiwari, MSc, Kaushal Mishra, PhD, Francois-Xavier Mahon, MD PhD

Blood (2019) 134 (Supplement_1): 2932.

https://doi.org/10.1182/blood-2019-129393

Published: 2019

Journal Articles

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

Robert J. Kreitman, MD, Claire E. Dearden, MD FRCP, FRCPath, Pier Luigi Luigi Zinzani, MD, Julio Delgado, Tadeusz Robak, MD, Philipp D le Coutre, MD, Bjorn T. Gjertsen, MD PhD, Xavier Troussard, MD, Gail J. Roboz, MD, Lionel Karlin, MD, Douglas E Gladstone, MD, Nataliya Kuptsova-Clarkson, MD, Shiyao Liu, Priti Patel, MD, Wyndham Wilson, MD, Ira Pastan, MD, Francis J. Giles, MD FRCPI, FRCPath

Blood (2019) 134 (Supplement_1): 2808.

https://doi.org/10.1182/blood-2019-122307

Published: 2019

Journal Articles

Targeting Both BET and Crebbp/EP300 Proteins with the Novel Dual Inhibitor NEO2734 Leads to More Preclinical Anti-Tumor Activity in Diffuse Large B Cell Lymphomathan with Single BET or Crebbp/EP300 Inhibitors

Filippo Spriano, Eugenio Gaudio, PhD, Chiara Tarantelli, PhD, Gaetanina Golino, Luciano Cascione, PhD, Emanuele Zucca, Anastasios Stathis, MD, Francis J. Giles, MD FRCPI, FRCPath, Francesco Bertoni, MD

Blood (2018) 132 (Supplement 1): 4174.

https://doi.org/10.1182/blood-2018-99-114900

Published: 2018

Journal Articles

Alisertib (MLN8237), an Oral Selective Inhibitor of Aurora Kinase a, Has Clinical Activity and Restores GATA1 Expression in Patients with Myelofibrosis

Blood (2018) 132 (Supplement 1): 688.

https://doi.org/10.1182/blood-2018-99-110381

Published: 2018

Journal Articles

Treatment-Free Remission (TFR) Among Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Not Initially Eligible for Treatment Discontinuation Due to Unstable Deep Molecular Response (DMR): Enestfreedom and Enestop

Timothy P. Hughes, MD, Andreas Hochhaus, MD, Dong-Wook Kim, MD PhD, Francois-Xavier Mahon, MD PhD, Francis J. Giles, MD MB, FRCPath, Jerald P. Radich, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Prashanth Gopalakrishna, MD, Weiping Deng, Rafik Fellague-Chebra, MD, Sandip Acharya, MSc, Giuseppe Saglio, MD PhD

Blood (2017) 130 (Supplement 1): 2878.

https://doi.org/10.1182/blood.V130.Suppl_1.2878.2878

Published: 2017

Journal Articles

A Multicenter, Open-Label, Pilot Study of Alisertib (MLN8237), a Novel Inhibitor of Aurora Kinase a, in Myelofibrosis

Blood (2017) 130 (Supplement 1): 1631.

https://doi.org/10.1182/blood.V130.Suppl_1.1631.1631

Published: 2017

Journal Articles

Molecular Recurrence-Free Survival (MRecFS) Following Imatinib Vs. Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Matched Analysis of Patients in EURO-SKI and Enestfreedom

Markus Pfirrmann, Francois-Xavier Mahon, MD PhD, Joelle Guilhot, PhD, Johan Richter, MD PhD, Francis J. Giles, MD MB, FRCPath, Andreas Hochhaus, MD, Jerald P. Radich, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Giuseppe Saglio, MD PhD, Weiping Deng, Darshan Dalal, MPH, MD PhD, Susanne Saussele, MD

Blood (2017) 130 (Supplement 1): 1601.

https://doi.org/10.1182/blood.V130.Suppl_1.1601.1601

Published: 2017

Journal Articles

Impact of Treatment Cessation on Overall Disease Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Attempting Treatment-Free Remission (TFR): Findings from Enestfreedom and Enestop

Giuseppe Saglio, MD PhD, Timothy P. Hughes, MD, Andreas Hochhaus, MD, Dong-Wook Kim, MD PhD, Francis J. Giles, MD MB, FRCPath, Jerald P. Radich, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Prashanth Gopalakrishna, MD, Weiping Deng, Rafik Fellague-Chebra, MD, Sandip Acharya, MSc, Francois-Xavier Mahon, MD PhD

Blood (2017) 130 (Supplement 1): 1598.

https://doi.org/10.1182/blood.V130.Suppl_1.1598.1598

Published: 2017

Journal Articles

Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTfreedom Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase

Andreas Hochhaus, MD, Maria Teresa Gómez Casares, MDPhD, Jesper Stentoft, MD PhD, Eibhlin Conneally, MB, MRCP, MRCPath, PhD, Valentin García-Gutiérrez, MD, Norbert Gattermann, MD, Wieslaw Wiktor-Jedrzejczak, MD, Philipp D. Le Coutre, MD, Bruno Martino, MD, Susanne Saussele, MD, Francis J. Giles, MB, MD FRCPI, FRCPath, Jerald P. Radich, David M. Ross, MBBS, PhD FRACP, FRCPA, Hans D. Menssen, MD PhD, Weiping Deng, Patricia Brandt, Ari Gnanasakthy, MBA, MSc, Veronique Bedoucha, Giuseppe Saglio, MD

Blood (2016) 128 (22): 3066.

https://doi.org/10.1182/blood.V128.22.3066.3066

Published: 2016

Journal Articles

Merestinib blocks Mnk kinase activity in acute myeloid leukemia progenitors and exhibits antileukemic effects in vitro and in vivo

Ewa M. Kosciuczuk, Diana Saleiro, Barbara Kroczynska, Elspeth M. Beauchamp, Frank Eckerdt, Gavin T. Blyth, Sameem M. Abedin, Francis J. Giles, Jessica K. Altman, Leonidas C. Platanias

Blood (2016) 128 (3): 410–414.

https://doi.org/10.1182/blood-2016-02-698704

Published: 2016

Includes: Supplemental data

Journal Articles

Phase 1 Dose-Escalation Study of TAK-659, an Investigational SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies

Adam M. Petrich, MD, Leo I. Gordon, MD, Jeffrey R. Infante, MD, Sumit Madan, MD, Francis J. Giles, MD, Halla S. Nimeiri, MBBS, Jason B. Kaplan, MD, Kate Stumpo, Bin Zhang, ScD, Stephanie Faucette, PharmD, PhD, Yaping Shou, MD PhD, Kent C. Shih, MD

Blood (2015) 126 (23): 2693.

https://doi.org/10.1182/blood.V126.23.2693.2693

Published: 2015

Journal Articles

Impact of Age on Efficacy and Toxicity of Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis

Blood (2015) 126 (23): 479.

https://doi.org/10.1182/blood.V126.23.479.479

Published: 2015

Journal Articles

Molecular Response with Nilotinib in Patients with Philadelphia Negative (Ph-) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis

Blood (2015) 126 (23): 4054.

https://doi.org/10.1182/blood.V126.23.4054.4054

Published: 2015

Journal Articles

Deep Molecular Responses In Patients With Newly Diagnosed Chronic Myeloid Leukemia Receiving Nilotinib As Assessed Within The EUTOS Laboratory Network In The ENEST1st Study

Blood (2013) 122 (21): 4030.

https://doi.org/10.1182/blood.V122.21.4030.4030

Published: 2013

Journal Articles

A Phase 1b, Dose-Finding Study Of Ruxolitinib Plus Panobinostat In Patients With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF): Identification Of The Recommended Phase 2 Dose

Vincen t Ribrag, Claire N Harrison, DM, FRCP, FRCPath, Florian H Heidel, MD, Jean-Jacques Kiladjian, MD, PhD, Suddhasatta Acharyya, PhD, Song Mu, PhD, Tracy Liu, Denise Williams, MD, Francis J Giles, MB, MD, FRCPI, FRCPath, Eibhlin Conneally, MB, MRCPI, FRCPath, PhD, Thomas Kindler, MD, Francesco Passamonti, MD, Alessandro M Vannucchi, MD

Blood (2013) 122 (21): 4045.

https://doi.org/10.1182/blood.V122.21.4045.4045

Published: 2013

Journal Articles

Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study,

Blood (2011) 118 (21): 3770.

https://doi.org/10.1182/blood.V118.21.3770.3770

Published: 2011

Journal Articles

Retrospective Cohort Analysis of Peripheral Arterial Occlusive Disease (PAOD) Events in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Francis J. Giles, MB, MD, FRCPI, FRCPath, Michael J. Mauro, MD, Frank Hong, MD, PhD, MPH, Christine-Elke Ortmann, Richard C. Woodman, Philipp D. LeCoutre, MD, Giuseppe Saglio, MD

Blood (2011) 118 (21): 2757.

https://doi.org/10.1182/blood.V118.21.2757.2757

Published: 2011

Journal Articles

A Phase IIIb Multicentre Open-Label Study of Nilotinib in Adult Patients with Newly Diagnosed BCR-ABL Positive Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A European Clinical Initiative with EUTOS Collaboration for Standardisation of Molecular Remission

Francis J. Giles, MB, MD, FRCPI, FRCPath, Gianantonio Rosti, MD, Gert Ossenkoppele, MD, PhD, Michel Tulliez, Jesper Stentoft, MD, PhD, Aristoteles Giagounidis, MD, Francesco Nobile, MD, Philipp D. le Coutre, MD, Norbert Gattermann, MD, Laimonas Griskevicius, Nicholas C.P. Cross, PhD, FRCPath, Sarah Hill, BSc (hons), PhD, MICR, Peter Schuld, PhD, Angela Pellegrino, Domenico Magazzù, Andreas Hochhaus, MD

Blood (2011) 118 (21): 2759.

https://doi.org/10.1182/blood.V118.21.2759.2759

Published: 2011

Journal Articles

Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib

Jorge E. Cortes, Andreas Hochhaus, Philipp D. le Coutre, Gianantonio Rosti, Javier Pinilla-Ibarz, Elias Jabbour, Kathryn Gillis, Richard C. Woodman, Rick E. Blakesley, Francis J. Giles, Hagop M. Kantarjian, Michele Baccarani

Blood (2011) 117 (21): 5600–5606.

https://doi.org/10.1182/blood-2010-11-318949

Published: 2011

NARROW

Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR 4.5 : Results from ENESTfreedom

Analyses of Predictors of Durable Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Frontline or Second-Line Nilotinib

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

Targeting Both BET and Crebbp/EP300 Proteins with the Novel Dual Inhibitor NEO2734 Leads to More Preclinical Anti-Tumor Activity in Diffuse Large B Cell Lymphomathan with Single BET or Crebbp/EP300 Inhibitors

Alisertib (MLN8237), an Oral Selective Inhibitor of Aurora Kinase a, Has Clinical Activity and Restores GATA1 Expression in Patients with Myelofibrosis

Treatment-Free Remission (TFR) Among Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Not Initially Eligible for Treatment Discontinuation Due to Unstable Deep Molecular Response (DMR): Enestfreedom and Enestop

A Multicenter, Open-Label, Pilot Study of Alisertib (MLN8237), a Novel Inhibitor of Aurora Kinase a, in Myelofibrosis

Molecular Recurrence-Free Survival (MRecFS) Following Imatinib Vs. Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Matched Analysis of Patients in EURO-SKI and Enestfreedom

Impact of Treatment Cessation on Overall Disease Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Attempting Treatment-Free Remission (TFR): Findings from Enestfreedom and Enestop

Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTfreedom Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase

Merestinib blocks Mnk kinase activity in acute myeloid leukemia progenitors and exhibits antileukemic effects in vitro and in vivo

Phase 1 Dose-Escalation Study of TAK-659, an Investigational SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies

Impact of Age on Efficacy and Toxicity of Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis

Molecular Response with Nilotinib in Patients with Philadelphia Negative (Ph-) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis

Deep Molecular Responses In Patients With Newly Diagnosed Chronic Myeloid Leukemia Receiving Nilotinib As Assessed Within The EUTOS Laboratory Network In The ENEST1st Study

A Phase 1b, Dose-Finding Study Of Ruxolitinib Plus Panobinostat In Patients With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF): Identification Of The Recommended Phase 2 Dose

Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study,

Retrospective Cohort Analysis of Peripheral Arterial Occlusive Disease (PAOD) Events in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

A Phase IIIb Multicentre Open-Label Study of Nilotinib in Adult Patients with Newly Diagnosed BCR-ABL Positive Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A European Clinical Initiative with EUTOS Collaboration for Standardisation of Molecular Remission

Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only